|
|
||||||||





Departments of*
Clinical Neurosciences and
Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada;
Department of Neurology, Johns Hopkins University, Baltimore, MD 21218;
Department of Immunology, Tehran University of Medical Sciences, Tehran, Iran; and ¶ Johnson & Johnson Pharmaceutical Research and Development, Spring House, PA 19477
Proteinase-activated receptors (PARs), a newly discovered subgroup of G-protein coupled receptors, are widely expressed by neural cells, but their roles in the nervous system remain uncertain. In this study, we report that PAR-2 was up-regulated on neurons in conjunction with neuroinflammation in brain tissue from patients with HIV-1-associated dementia. The inflammatory cytokines TNF-
and IL-1
were also increased in HIV-1-associated dementia brains compared with patients without dementia (p < 0.05), but these same cytokines induced PAR-2 expression on neurons. Enhanced PAR-2 expression and subsequent activation prevented neuronal cell death and induction of the tumor suppressor, p53, caused by the HIV-encoded protein, Tat (p < 0.01). Intrastriatal implantation of a PAR-2 peptide agonist also inhibited Tat-induced neurotoxicity in a mouse model of HIV neuropathogenesis (p < 0.05). Moreover, PAR-2 null animals showed more severe neuroinflammation and neuronal loss caused by Tat neurotoxicity (p < 0.05). TNF-
protected wild-type neurons from Tat-related neurotoxicity, but in PAR-2-deficient neurons, the same concentrations of TNF-
were cytotoxic (p < 0.001). Thus, neuroinflammation can exert protective effects by which it induces PAR-2 expression with the ensuing abrogation of neuronal death.
This article has been cited by other articles:
![]() |
Y. Zhu, D. Vergote, C. Pardo, F. Noorbakhsh, J. C. McArthur, M. D. Hollenberg, C. M. Overall, and C. Power CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy FASEB J, September 1, 2009; 23(9): 2928 - 2941. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Shpacovitch, M. Feld, M. D. Hollenberg, T. A. Luger, and M. Steinhoff Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity J. Leukoc. Biol., June 1, 2008; 83(6): 1309 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Moraes, R. Martin, J. D. Plumb, E. Vachon, C. M. Cameron, A. Danesh, D. J. Kelvin, W. Ruf, and G. P. Downey Role of PAR2 in murine pulmonary pseudomonal infection Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L368 - L377. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Jiang, A. Zatta, H. Kin, N. Wang, J. G. Reeves, J. Mykytenko, J. Deneve, Z.-Q. Zhao, R. A. Guyton, and J. Vinten-Johansen PAR-2 activation at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2845 - H2852. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. van Marle, J. Antony, H. Ostermann, C. Dunham, T. Hunt, W. Halliday, F. Maingat, M. D. Urbanowski, T. Hobman, J. Peeling, et al. West Nile Virus-Induced Neuroinflammation: Glial Infection and Capsid Protein-Mediated Neurovirulence J. Virol., October 15, 2007; 81(20): 10933 - 10949. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Afkhami-Goli, F. Noorbakhsh, A. J. Keller, N. Vergnolle, D. Westaway, J. H. Jhamandas, P. Andrade-Gordon, M. D. Hollenberg, H. Arab, R. H. Dyck, et al. Proteinase-Activated Receptor-2 Exerts Protective and Pathogenic Cell Type-Specific Effects in Alzheimer's Disease J. Immunol., October 15, 2007; 179(8): 5493 - 5503. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Bushell The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders J. Physiol., May 15, 2007; 581(1): 7 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ramachandran, L. R. Sadofsky, Y. Xiao, A. Botham, M. Cowen, A. H. Morice, and S. J Compton Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4 Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L788 - L798. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vergote, G. S. Butler, M. Ooms, J. H. Cox, C. Silva, M. D. Hollenberg, J. H. Jhamandas, C. M. Overall, and C. Power Proteolytic processing of SDF-1{alpha} reveals a change in receptor specificity mediating HIV-associated neurodegeneration PNAS, December 12, 2006; 103(50): 19182 - 19187. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Noorbakhsh, S. Tsutsui, N. Vergnolle, L. A. Boven, N. Shariat, M. Vodjgani, K. G. Warren, P. Andrade-Gordon, M. D. Hollenberg, and C. Power Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis J. Exp. Med., February 21, 2006; 203(2): 425 - 435. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |